Sequenta, Chronix Pursue NGS Tests for Minimal Residual Disease in Cancer Patient Blood Samples | GenomeWeb

At recent clinical meetings, two firms — Sequenta and Chronix Biomedical — presented data illustrating the distinct next-generation sequencing-based strategies each is taking to monitor minimal residual disease in cancer patients.

At this year's American Society of Clinical Oncology meeting in Chicago, for instance, Chronix researchers co-authored a poster showing that it was possible to track MRD after surgery in women with breast cancer using tumor markers found in blood samples taken prior to surgery.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: variant protective against Alzheimer's disease, effect of whole-genome duplication on methylation in rice, and more.

Genome editing is also bringing up questions when applied to farm animals, the New York Times reports.

Through a transcriptome study, researchers home in on the activity of inflammation-linked genes in chronically lonely people.

Determining who is and is not an author and where a researcher should fall on a list of authors can be a tricky task, Nature News writes.